Abstract
Concerns are increasing that the drugs we have used to treat this chronic pulmonary infection will cease to work because of development of resistance, raising the threat of untreatable disease. This review explains the molecular and clinical basis of resistance. The current best practice for the treatment of multi-drug resistance is described. There are a number of new drugs and regimens currently under investigation and these are described. The importance of improved case finding, diagnosis and early treatment are emphasised.
Keywords: Antibiotic resistance, drug treatment, extremely drug resistant, multidrug resistance, tuberculosis.
Current Respiratory Medicine Reviews
Title:MDR/XDRTB: What are the New Treatment Options?
Volume: 9 Issue: 3
Author(s): Stephen H. Gillespie
Affiliation:
Keywords: Antibiotic resistance, drug treatment, extremely drug resistant, multidrug resistance, tuberculosis.
Abstract: Concerns are increasing that the drugs we have used to treat this chronic pulmonary infection will cease to work because of development of resistance, raising the threat of untreatable disease. This review explains the molecular and clinical basis of resistance. The current best practice for the treatment of multi-drug resistance is described. There are a number of new drugs and regimens currently under investigation and these are described. The importance of improved case finding, diagnosis and early treatment are emphasised.
Export Options
About this article
Cite this article as:
Gillespie H. Stephen, MDR/XDRTB: What are the New Treatment Options?, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990018
DOI https://dx.doi.org/10.2174/1573398X113099990018 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-infective Agents Produced by the Hyphomycetes Genera Trichoderma and Gliocladium
Current Medicinal Chemistry - Anti-Infective Agents Virtual Screening: Are We There Yet?
Mini-Reviews in Medicinal Chemistry Bioactive Secondary Metabolites from Endophytic Fungi
Current Medicinal Chemistry Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Histopathological Scores for Tissue-Engineered, Repaired and Degenerated Tendon: A Systematic Review of the Literature
Current Stem Cell Research & Therapy Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Studies of Substituted 1, 2, 3, 4- Tetrahydro Pyrimidine Phosphorus Derivatives
Combinatorial Chemistry & High Throughput Screening Synthesis and Characterization of Some New Thiazole based Thiazolidinone Derivatives as Potent Antimicrobial and Antimycobacterial Agents
Anti-Infective Agents Recombinant Mycobacterium bovis BCG as an HIV Vaccine Vector
Current HIV Research In Vitro Antimycobacterial Activity of New 7-Chloroquinoline Derivatives
Letters in Drug Design & Discovery Non-Antidepressant Treatment of Social Anxiety Disorder: A Review
Current Clinical Pharmacology Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Current Medicinal Chemistry Editorial
Current Drug Targets - Infectious Disorders Vaccine Development for Potential Bioterrorism Agents
Current Drug Targets - Infectious Disorders Collocating Novel Targets for Tuberculosis (TB) Drug Discovery
Current Drug Discovery Technologies Genotyping and Drug Susceptibility Patterns of <i>M. Tuberculosis</i> Isolated from HIV Seropositive Patients in Tehran Iran
Current HIV Research Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Current Molecular Pharmacology The TB Structural Genomics Consortium: Providing a Structural Foundation for Drug Discovery
Current Drug Targets - Infectious Disorders Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Subject Index To Volume 8
Protein & Peptide Letters